This randomized, multicentre, double-blind, double-dummy study assessed the efficacy and safety of 7 or 10 day regimens of grepafloxacin, 600 mg od, compared with amoxycillin, 500 mg tds, in the treatment of community-acquired pneumonia (CAP). A total of 264 patients were recruited at 43 centres (127 received grepafloxacin and 137 received amoxycillin), of whom 207 patients (78%) completed the study. Clinical and microbiological efficacy were assessed at the end-of-treatment visit (3-5 days after the last dose) and at the follow-up visit (28-42 days after the last dose). At follow-up, patients in the evaluable population treated with grepafloxacin demonstrated a clinical response rate (76%; 87/114) equivalent to that seen with amoxycillin (74%, 85/111, 95% CI = -12%, 10%) while, in the intent-to-treat population with a documented bacterial pathogen, the clinical success rate in the grepafloxacin group (78%, 29/37) was significantly higher than in the amoxycillin group (58%, 28/48), 95% CI = 2%, 43%). In patients from the evaluable population in whom the pathogens were documented the clinical success rate favoured grepafloxacin, compared with amoxycillin (79%, 26/33 versus 63%, 26/42, respectively; 95% CI = -5.2%, 38.1%). Microbiological eradication with grepafloxacin was statistically superior to amoxycillin in the evaluable population; the success rate was 89% (32/36) in the grepafloxacin group compared with 71% (32/45) for the amoxycillin group (95% CI = 2%, 37%). The pathogens most commonly isolated from patients were Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae. The success rates for infections caused by S. pneumoniae and H. influenzae at follow-up were higher with grepafloxacin than with amoxycillin. Grepafloxacin was well tolerated, with a safety profile comparable to that of amoxycillin. The therapeutic judgement of patients and investigators at the patient's last visit, as well as the assessment of individual respiratory signs and symptoms, yielded comparable results with both treatments. The results of this study indicate that grepafloxacin, 600 mg od for 7-10 days, is equivalent to or better than amoxycillin, 500 mg tds for 7-10 days in achieving a successful clinical and microbiological response in the treatment of patients with CAP.
Introduction
Community-acquired pneumonia (CAP) is defined as pneumonia unrelated to hospitalization, and has presenting signs and symptoms similar to those of acute bacterial exacerbations of chronic bronchitis, i.e. increased cough, dyspnoea, rapid respiratory rate and sputum production. Severe CAP is associated with considerable morbidity and mortality; the overall mortality rate is around 3%, rising to 11% in patients with bacteraemia, 1 and in the USA, CAP remains a leading infectious cause of death. 2 Nevertheless, a recent review of strategies for management of CAP 3 discusses a predictive model which allows patients to be stratified according to their risk of mortality and other adverse events, thus reflecting initial disease severity. Using this model, physicians can identify low-risk patients who are candidates for treatment in the community. The range of pathogens associated with CAP is wide and ever-expanding, and the susceptibility of some to available antimicrobial drugs is decreasing. The pathogens frequently associated with CAP are Streptococcus pneumoniae, Haemophilus 10 Atypical pneumonias account for around 10% of pneumonia cases. 11 These figures suggest that monotherapy with antibiotics such as amoxycillin/ampicillin and particularly penicillin, may not always be appropriate.
In patients without underlying disease, bacterial CAP can be treated in the outpatient setting using oral antibiotics. If initial therapy with an oral penicillin, cephalosporin or macrolide fails, or when infection with a Gram-negative organism is suspected, an oral quinolone, such as ofloxacin or ciprofloxacin, is often recommended. 12 Grepafloxacin is a new-generation oral fluoroquinolone with enhanced activity against Gram-positive organisms, 13 which is currently under investigation for the treatment of community-acquired respiratory infection. In-vitro studies have shown that grepafloxacin, in contrast to older fluoroquinolones, has enhanced activity against S. pneumoniae (irrespective of the strain's susceptibility to penicillin), 14 Enterococci and methicillin-susceptible S. aureus. [13] [14] [15] [16] Grepafloxacin also exhibits superior activity to amoxycillin against H. influenzae (including -lactamase-producing and/or ampicillin-resistant strains) and M. catarrhalis, including -lactamase producers. 14, 16 Multiple-dose studies with grepafloxacin 600 mg (oncedaily dosing for 14 days) have demonstrated peak plasma concentrations of 2.3 mg/L approximately 2 h after oral administration, with an elimination half-life of up to 15 h at steady state (Glaxo-Wellcome, data on file), allowing a once-daily dose regimen. This peak level is greatly in excess of grepafloxacin MIC 90 s for H. influenzae and M. catarrhalis (0.02 mg/L), and S. pneumoniae (0.25 mg/L). 13 A recent study has also shown that grepafloxacin has excellent penetration into lung tissues (including epithelial lining fluid and bronchial mucosa), attaining higher concentrations in lung tissues than in serum. 17 Thus, grepafloxacin would appear to be a highly suitable agent for the treatment of CAP.
In order to investigate its efficacy and tolerance in patients with CAP, grepafloxacin was compared with amoxycillin, a commonly prescribed broad-spectrum antibacterial agent.
Materials and methods
This was a randomized, double-blind, double-dummy study performed at 43 centres in the UK and Ireland. The study protocol was approved by an Ethics Committee (Institutional Review Board equivalent) and writteninformed patient consent was obtained in accordance with the Declaration of Helsinki and with national guidelines. Eligible patients were aged between 18 and 80 years, with an established diagnosis (radiographic and consistent signs and symptoms) of suspected bacterial CAP suitable for treatment with an oral antibiotic on an outpatient basis. Clinical signs and symptoms must have included at least three of the following: cough, pyrexia, dyspnoea, decreased air entry and/or localized crackles. All patients had a chest X-ray showing signs and symptoms consistent with a diagnosis in the 24 h prior to the study or in the following 24 h.
At the pre-treatment visit patients were screened and baseline physical examinations and clinical laboratory tests were performed. Dosing began within 24 h of these pretreatment assessments. Patients eligible for inclusion received grepafloxacin 600 mg od or amoxycillin 500 mg tds for 7 to 10 days. Patients were evaluated at the duringtreatment visit (days 3-5) to perform clinical respiratory assessments and to investigate adverse events, vital signs and changes in concomitant medication. After 7 days of treatment the investigator decided whether to stop medication (7 days of therapy) or to continue for an additional 3 days (10 days of therapy). Efficacy was assessed at two post-treatment time points; the end-of-treatment visit (3-5 days after the last dose) and the follow-up visit (28-42 days after the last dose). The primary efficacy assessments were conducted at the follow-up visit.
Exclusion criteria
Patients meeting any of the following criteria were excluded: allergy to quinolone or penicillin antibiotics; pregnancy or lactation; women of childbearing potential not using acceptable contraception; evidence of a lung tumour, active tuberculosis or cystic fibrosis; current history or clinical signs of hepatic or renal impairment; current history of seizure disorders; malabsorption syndromes; respiratory tract infection requiring parenteral antimicrobial therapy; concomitant treatment with antimicrobial therapy other than topical or antifungal agents; treatment with other oral antibiotics within 3 days or with a longacting injectable antibiotic within 1 week before starting the study, unless the organism was resistant to the antibiotic used and the patient was a clinical treatment failure; previous participation in this or any other clinical trial with grepafloxacin; treatment with an investigational drug or device before 4 weeks of study entry; concomitant treat-ment with theophylline; chronic treatment with fenbufen, warfarin or probenecid; required inhalation of, or increase in dose of, systemic steroids for the treatment of respiratory tract infections; or terminal illness or immunocompromised status.
Evaluation of symptoms
Clinical progress was monitored by the investigator at the during-treatment, end-of-treatment and follow-up visits. Any patient whose clinical condition had worsened by day 3 or was unchanged by day 5 was assessed as a clinical failure, withdrawn and placed on alternative therapy. Patients were asked to assess the following: cough severity, sputum volume, haemoptysis, dyspnoea severity and chest pain. The investigator assessed sputum colour, mucopurulence and thickness, the presence or absence of adventitious sounds, friction sounds, decreased air entry and the patient's respiratory rate.
Bacteriological testing
Expectorated sputum samples were collected from patients before randomization and from those able to raise sputum at the during-treatment, end-of-treatment and follow-up visits. These samples were used for Gram staining and, if acceptable (i.e. with 10 epithelial cells and 25 white blood cells per low power field), for culture and quantitative assessment of morphologically distinct bacterial cells. Acceptable bacterial pathogens included S. pneumoniae, H. influenzae and M. catarrhalis or a bacterial isolate deemed by the investigator to be the causative organism of the infection. All species of Haemophilus, Moraxella and Staphylococcus isolated were tested for -lactamase production, and all staphylococci were screened for methicillin resistance. In addition, subsequent to study completion, all S. pneumoniae isolates were tested for penicillin susceptibility.
All cultures isolated were tested for susceptibility to grepafloxacin, ciprofloxacin, ofloxacin, amoxycillin, erythromycin, cefaclor, co-amoxiclav and co-trimoxazole by broth microdilution. Serological tests of 'atypical' pathogens were not performed.
Criteria for efficacy assessment
The primary efficacy outcome variables were clinical response, determined by clinical serial evaluations of the patient to assess the effect of therapy on the signs and symptoms of CAP, and microbiological response, based on the evaluation of cultures from pre-treatment and posttreatment sputum specimens, to determine the effect of therapy on the pathogens causing CAP. The secondary efficacy outcome variable was the radiological response, based on the evaluation of pre-treatment and posttreatment chest radiographs. After study completion, therapeutic judgement by the patient and investigator and assessment of individual clinical signs and symptoms of CAP were also analysed as secondary efficacy variables.
Clinical outcome
Patients assessed as clinical failures at the end-oftreatment visit were withdrawn and started on alternative therapy. Those assessed as a cure or improvement had a final clinical response assessment performed at the followup visit. At this visit, clinical response was assessed as follows: cure (resolution of signs and symptoms that established the diagnosis of CAP); improvement (reduction in the severity and/or number of signs and symptoms); failure (persistence or worsening of the signs or symptoms, or development of new signs and symptoms of CAP); or indeterminate (evaluation not possible). For the determination of clinical outcome, success represented the combination of cure and improvement.
Microbiological outcome
The microbiological response to treatment was rated using the following protocol-specified criteria: eradication (original causative organism absent); presumed eradication (no sputum produced because of clinical improvement); persistence (continued presence of causative organism); presumed persistence (no sputum obtained, and additional antimicrobial therapy needed for continued infection at the same site); superinfection (new infecting organism arising during therapy, associated with new or worsening clinical signs and symptoms); colonization (new, potentially pathogenic organism occurring after the start of therapy but without signs and symptoms of infection); recurrence (absence of the original causative organism at the end of therapy but recurrence of infection with the same organism at follow-up, associated with clinical signs and symptoms of CAP); reinfection (absence of the original causative organism at the end of therapy but reinfection with a new organism after the end of therapy, associated with new or worsening clinical signs and symptoms of CAP); or indeterminate (evaluation not possible).
If the patients had stopped producing sputum and had a clinical response of cure or improvement, the microbiological response was assessed as presumed eradication. If the patient had stopped producing sputum and the clinical response was failure, the microbiological response was assessed as presumed persistence. Final microbiological response assessments were conducted at the follow-up visit. Microbiological responses of eradication, presumed eradication, eradication with contamination/colonization, eradication with infection and eradication with superinfection were combined as microbiological success as, in all these cases, the original causative pathogen had been eliminated. Microbiological responses of persistence, presumed persistence and recurrence were combined as microbiological failure.
Radiological assessment
The patients' radiological responses were assessed by examination of chest radiographs taken at the pre-treatment and end-of-treatment visits. A radiograph was only required at the follow-up visit if there were continued signs of infection at this visit. Radiographic response was assessed using the following criteria: resolution (disappearance of all radiographic signs of CAP); improvement (reduction in the number or intensity of radiographic signs of CAP); persistence (no change or worsening of the radiographic signs of CAP); or indeterminate (evaluation not possible).
The radiographic response was assessed at the end-oftreatment visit and responses of resolved and improved were defined as radiographic success and persistence as radiographic failure. The radiographic response was not assessed at the follow-up visit because a chest radiograph was only performed in patients with persisting clinical signs and symptoms of infection.
Patient populations
Four patient populations were used for statistical analysis: the intent-to-treat (ITT) population (all patients randomized into the study who received at least one dose of study medication); the evaluable population (those ITT patients who complied with the study protocol), and ITT and evaluable populations who had pathogen(s) isolated from acceptable pretreatment sputum specimens. Clinical response was assessed for all four patient populations, while microbiological response was evaluated only for the populations in which pathogens were isolated. However, this paper will focus primarily on the analyses of the clinical response in the evaluable patient population and of the microbiological response in the evaluable patient population.
Sample size and statistical methods
The sample size for this study was calculated based on the method of Makuch & Simon 18 to establish equivalence between grepafloxacin and amoxycillin using a 95% confidence interval for the difference in clinical response rate. The lower limit of the confidence interval, together with the individual response rates, was used to establish equivalence. For primary clinical and microbiological efficacy endpoints with values of 90% for the better of the two treatments, a confidence interval crossing zero and remaining within a lower limit delta of 0.1 (i.e. 10%) or more is needed to establish equivalence. For those endpoints with values of 80-89% for the better treatment, a confidence interval crossing zero and remaining within a lower limit delta of 0.15 or more is needed to establish equivalence. For endpoints with values of 80% for the better treatment, a confidence interval crossing zero and remaining within a lower limit delta of 0.2 or more is needed to establish equivalence.
Assessment of equivalence was made based on a twotailed 95% confidence interval around the difference in outcomes. A 95% two-sided confidence interval for this difference was calculated using the Mantel-Haenszel method based on a centre-weighted average of the differences across centres.
Respiratory assessments
Changes in individual respiratory signs and symptoms for patients in the grepafloxacin group were compared with changes in the amoxycillin group. Results were analysed for the ITT population and ITT patients who had pathogen(s) isolated from acceptable pre-treatment sputum specimens.
Safety assessments
The following safety assessments were performed: monitoring for adverse events; clinical laboratory tests; vital signs and weight; and physical examination. Safety data were analysed for the ITT group only. Adverse events were recorded on the clinical trial form on the basis of the patient's own observations and categorized on the basis of an FDA COSTART classification. An adverse event was defined to be any sign/symptom that occurred after the patient had started medication or a pre-existing condition whose severity or frequency increased after the patient had started study medication. An adverse event was classified as serious if it was fatal or life threatening, permanently disabling, required hospitalization or was a congenital anomaly, cancer or overdose. Treatment-related adverse events were those judged by the investigator to be possibly or probably related to a study drug, and those for which a drug relationship was indicated as 'unknown'.
Patient withdrawals
Patients were withdrawn from the study for the following reasons: significant protocol violation; non-compliance as judged by the investigator; baseline chest radiograph taken within 24 h after the start of treatment showing no evidence of CAP; worsening of the patient's condition after 3 days or lack of improvement after 5 days of treatment; adverse events; and at the patient's or physician's request.
Results
A total of 264 patients were enrolled in this study between September 1992 and November 1993, of whom 127 received grepafloxacin 600 mg od and 137 received amoxycillin 500 mg tds for 7 or 10 days. The demographic and pretreatment characteristics of the ITT population are shown in Table I . No statistically significant differences were seen between the treatment groups for any demographic parameters at baseline.
Of the 264 patients recruited, 207 (78%) completed the study, 103 (81%) in the grepafloxacin group and 104 (76%) in the amoxycillin group. A total of 57 patients was withdrawn prematurely, 24 (19%) from the grepafloxacin group and 33 (24%) from the amoxycillin group. The primary reasons for withdrawal were lack of response, adverse events and patients not satisfying the screening criteria (e.g. negative chest radiograph). Thirty patients (11%) were withdrawn because of a lack of response, 12 (9%) in the grepafloxacin group and 18 (13%) in the amoxycillin group.
Clinical response
The overall clinical success rates for the evaluable population at the follow-up visit were as follows. The success rate in patients receiving grepafloxacin was 76.3% (87/114), compared with 76.6% (85/111) in the amoxycillin group. The 95% CI confirmed the equivalence of the two treatments in this population (95% CI 12%, 10%). Results from ITT patients with a documented bacterial pathogen, showed the success rate in the grepafloxacin group (78%, 29/37) to be significantly higher than in the amoxycillin group (58%, 28/48, 95% CI 2%, 43%). In patients from the evaluable population with a documented pathogen, the success rate favoured grepafloxacin compared with amoxycillin (79%, 26/33 versus 63%, 26/42, respectively; 95% CI 5.2%, 38.1%) For patients in the evaluable population in whom S. pneumoniae was isolated the success rates were 83.3% (15/18 patients) for grepafloxacin and 50% (6/12 patients) for amoxycillin. This success rate was similar in patients in the evaluable population with H. influenzae infection: 83.3% (15/18) for grepafloxacin and 66.7% (16/24) for amoxycillin, reflecting the microbiological superiority of grepafloxacin.
Microbiological response
Of the 264 patients who entered the study, 81 were evaluable microbiologically. The microbiological success rates at the follow-up visit for all pathogens combined in the evaluable population was significantly higher in the grepafloxacin group (89%, 32/36 isolates) than in the amoxycillin group (71%, 32/45 isolates; 95% CI 2%, 37%), as was also seen for the microbiological success rates in the evaluable population at the end-of-treatment visit (100% vs 81%; 95% CI 7%, 33%) (data not shown).
For the commonly isolated pathogens in the evaluable population at end-of-treatment, S. pneumoniae was eradicated in 100% of patients in both groups (n 20 for 
Isolated pathogens
The pathogens most commonly isolated were H. influenzae (48%), S. pneumoniae (38%) and M. catarrhalis (7%). Higher numbers of H. influenzae (28 vs 19 isolates) and M. catarrhalis strains (six vs one isolate) were isolated from patients in the amoxycillin group, and more S. pneumoniae isolates were obtained from patients from the grepafloxacin group (22 vs 15 isolates). Based on the breakpoints proposed for this study, 23 pathogens isolated from 22 patients in the ITT population demonstrated resistance or intermediate susceptibility to the treatment drugs at the pre-treatment evaluation; five to grepafloxacin, 17 to amoxycillin and one to both agents. One of the grepafloxacin-resistant pathogens (H. influenzae; MIC 0.12 mg/L) was isolated from a patient who subsequently received grepafloxacin and was rated a clinical success at the follow-up visit. Breakpoint MIC for H. influenzae for the study was set at 0.06 mg/L. Approved NCCLS susceptibility breakpoint is MIC 0.5 mg/L. It should be noted, however, that in addition, six S. pneumoniae isolates with intermediate susceptibility to amoxycillin were identified; four from patients who subsequently received grepafloxacin and two from patients who received amoxycillin. The clinical response at the follow-up visit was rated as a success for five of these patients: the four who received grepafloxacin and one receiving amoxycillin. No grepafloxacin-resistant strains of S. pneumoniae were isolated in this study based on proposed breakpoints.
In those bacteria for which MIC data were available, 98% of grepafloxacin-treated pathogens (41/42) were susceptible to grepafloxacin and 82% of amoxycillintreated pathogens (40/49) were susceptible to amoxycillin. The clinical success rate for patients with grepafloxacinsusceptible pathogens treated with grepafloxacin at the follow-up visit was 78% (32/41). In the amoxycillin group the success rate at follow-up for patients with amoxycillinsusceptible pathogens was 60% (24/40). The patient yielding the only grepafloxacin-resistant pathogen who was treated with grepafloxacin was a clinical success at the follow-up visit. For the nine patients yielding amoxycillinresistant pathogens who were treated with amoxycillin, five (56%) were clinical successes at the follow-up visit.
Therapeutic judgement of efficacy
The numbers of investigators and patients in the microbiologically and clinically evaluable population making a therapeutic judgement of improvement at the final visit (whether the final scheduled visit or an early withdrawal visit) are shown in Table III . These judgements indicated that the treatment groups were comparable for therapeutic improvement in these patient populations, at least as measured by these parameters, though judgements of both patients and investigators were more favourable in the grepafloxacin group.
Radiological response
Analysis at the end-of-treatment visit indicated that the radiological response was greater in the grepafloxacin group than the amoxycillin group for all patient populations, but this was not statistically significant. In the clinically evaluable population, 89% of patients receiving grepafloxacin (101/114) and 87% (103/119) receiving amoxycillin were considered radiological successes.
Adverse events
A total of 32% of patients (41/127) receiving grepafloxacin 600 mg od and 24% (33/137) receiving amoxycillin 500 mg tds reported experiencing one or more drug-related, treatment-emergent adverse events. A summary of the drugrelated adverse events occurring with an incidence over 2% in the ITT population is given in Table IV . The most common adverse events in the grepafloxacin treatment group were nausea (13/127 patients, 10%) and taste alteration (7/127, 6%), and that in the amoxycillin group was diarrhoea (5/137 patients, 4%). There was only one case of photosensitivity, a known side-effect of quinolone therapy, in the grepafloxacin group, which was assessed as moderate in severity.
Treatment withdrawals
In all, ten patients (6%) discontinued study medication because of 14 adverse events. These included eight patients (6%) receiving grepafloxacin and two patients (2%) receiving amoxycillin. In nine of these patients, the adverse events were considered to be drug-related. The most commonly reported events among these patients were nausea (30%, 3/10), vomiting (20%, 2/10) and headache (20%, 2/10). Two deaths from myocardial infarction were reported, both in the grepafloxacin group, one occurring 5 days after the end of treatment and the other occurring 9 days after the end of treatment. Neither death was considered by the investigator to be related to the study drug.
Laboratory tests
Slight decreases in alkaline phosphatase, neutrophils and white blood cell count, and a small increase in cholesterol were seen at the end-of-treatment and follow-up visits in both treatment groups (Table V) . There were also moderate increases in uric acid at these visits in the grepafloxacin group, and smaller increases in the amoxycillin group. No unique laboratory findings were seen in either treatment group at the end-of-treatment or follow-up visits.
Discussion
Despite recent, significant advances in drug therapy and medical technology, both of which have had great impact /L) on the course of many diseases, pneumonia continues to present a challenge to clinicians. One of the principal reasons for this is the wide range of causative pathogens, and their changing patterns of susceptibility to the available antibacterial agents. Of particular concern is the increasing incidence of antibiotic resistance, particularly to penicillin in S. pneumoniae and to -lactams in Haemophilus spp.
The prognosis for patients with CAP ranges from rapid recovery to death, 19 but difficulty in assessing the severity of disease results in considerable variability in the rate of patient hospitalization. In a recent review, Fine et al. 3 propose that treatment strategies for patients with CAP can be based on a prognostic prediction rule, which stratifies patients according to their risk of mortality and other adverse events (i.e. reflecting the degree of severity of their pneumonia). Using this rule, the authors have proposed five risk classes which enable clinicians to identify patients at low risk (classes I-III, around 40% of patients), who can be considered for management in the community. The predictive variables from which the risk classes are derived can all be assessed at the time of patient presentation.
This paper describes a randomized, multicentre, doubleblind study comparing the efficacy and safety of grepafloxacin, 600 mg od with amoxycillin 500 mg tds for 7-10 days in patients with CAP who were considered by participating clinicians to be suitable for management in the community. In those patients with a documented bacterial infection, grepafloxacin was found to be superior to amoxycillin in producing a successful clinical response. Overall, grepafloxacin was equivalent to amoxycillin in achieving a successful clinical response and in achieving a successful microbiological response in the treatment of patients with CAP. In terms of microbiological eradication, grepafloxacin was statistically superior to amoxycillin at both the end-of-treatment and follow-up visits in the evaluable patient population. Grepafloxacin also showed significantly higher microbiological success rates against the pathogens most commonly isolated in this study. For patients in the evaluable population receiving grepafloxacin, the success rates for both H. influenzae and S. pneumoniae isolates were 100% at end-of-treatment and 88% at follow-up. By contrast, for patients receiving amoxycillin in the evaluable population, success rates at end-of-treatment were 100% for S. pneumoniae and 76% for H. influenzae while, at follow-up, the success rate was reduced to 67% for both pathogens. No comparison of the two agents was possible for M. catarrhalis since no M. catarrhalis strains were isolated from microbiologically evaluable grepafloxacin-treated patients.
The two treatment groups showed comparable improvements in individual respiratory parameters, such as cough severity and adventitious sounds. The two groups also had comparable ratings of therapeutic improvement as judged by patients and investigators, though in both cases these ratings were slightly higher in the grepafloxacin group.
There was no significant difference in radiological response between the two groups, though the success rates favoured grepafloxacin. Both grepafloxacin and amoxycillin were generally well tolerated with comparable safety profiles, though the incidence of drug-related nausea was higher in the grepafloxacin group. Photosensitivity, a known sideeffect of quinolones, only occurred in one patient receiving grepafloxacin; a recent study has shown that grepafloxacin has a similar potential for photosensitivity as ciprofloxacin. 20 In conclusion, grepafloxacin, 600 mg od for 7-10 days is an effective and well-tolerated treatment for patients with CAP, and is likely to offer clinicians another option in the face of increasing antibiotic resistance. The activity of grepafloxacin against the organisms commonly associated with CAP suggest it may represent a valuable alternative in the management of such infections. Its once-daily dosing regimen, which may enhance patient compliance, 21 also supports its use as outpatient therapy for patients with CAP.
